8-K: DiaMedica Therapeutics Advances Clinical Trials, Reports Q3 2026 Results

DiaMedica Therapeutics reported progress in its Phase 2 Fetal Growth Restriction and Phase 2/3 Acute Ischemic Stroke trials, alongside third-quarter 2026 financial results, projecting cash runway into Q4 2027.

Summary

• DiaMedica Therapeutics announced progress in its clinical programs for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS).
• Enrollment is complete for the first two cohorts of the Phase 2 early-onset FGR trial, with preliminary results expected November 24.
• The ReMEDy2 Phase 2/3 AIS trial has surpassed 200 participants, triggering a planned interim analysis in Q1 2027.
• Health Canada and the European Medicines Agency (EMA) have authorized Phase 2 early-onset PE studies.
• The company reported $34.9 million in cash, cash equivalents, and short-term investments as of September 30, 2026, with a projected runway into Q4 2027.
• R&D expenses increased to $9.2 million for Q3 2026 and $25.4 million for the nine months ended September 30, 2026.
• Net losses for Q3 2026 were $11.3 million, and $31.5 million for the nine months ended September 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, with significant clinical trial progress and a clear cash runway, though increased R&D spending and net losses are noted.

Positives

• Enrollment completed in the first two cohorts of the Phase 2 early-onset FGR trial.
• ReMEDy2 Phase 2/3 AIS trial has enrolled over 200 participants, enabling the interim analysis.
• Phase 2 early-onset PE studies received authorization from Health Canada and conditional authorization from the EMA.
• Projected cash runway extends into Q4 2027, providing operational funding.
• Preliminary results from FGR cohorts to be presented at a KOL event on November 24.
• Interim analysis for the ReMEDy2 trial is expected in Q1 2027.

Negatives

• Net losses increased to $11.3 million for Q3 2026 and $31.5 million for the nine months ended September 30, 2026.
• R&D expenses increased significantly to $9.2 million for Q3 2026 and $25.4 million for the nine months ended September 30, 2026.
• Cash, cash equivalents, and short-term investments decreased to $34.9 million from $59.9 million at the end of 2025.
• Working capital decreased to $28.0 million from $55.5 million at the end of 2025.

Risks

• The FDA feedback regarding nonclinical reproductive toxicity information for the preeclampsia IND application requires further data submission.
• The conditional authorization from the EMA for the early-onset PE Phase 2 trial requires full approval after country-specific requirements are met.
• The ReMEDy2 interim analysis could result in a sample-size re-estimation or stopping for futility, potentially increasing costs and delaying completion.
• Risks associated with the timing and outcomes of nonclinical studies and clinical trials.
• Potential impact of hospital and medical facility staffing shortages, increased tariffs, and global supply chain shortages on clinical trial progress.

Future Outlook

The company anticipates its current cash, cash equivalents, and short-term investments will fund planned clinical studies and corporate operations into Q4 2027. R&D expenses are expected to moderately increase, while G&A expenses are expected to remain steady.

Management Comments

• During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.
• We believe these programs address serious diseases in which impaired blood flow and vascular dysfunction play a meaningful role and where new treatment options are needed.
• We look forward to presenting preliminary results from the first two FGR cohorts at our November 24 key opinion leader (KOL) event and to the ReMEDy2 interim analysis expected in the first quarter of 2027.
• Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.
• In preeclampsia, the Part 1a results demonstrated rapid and sustained reductions in maternal blood pressure and supported advancement into studies of early-onset disease.
• In FGR, enrollment of the first two dose cohorts has now been completed, and we look forward to reviewing the preliminary safety and clinical findings with leading maternal-fetal medicine experts later this month.
• In ReMEDy2, reaching the 200-participant threshold enables the prespecified interim analysis in AIS once the 200th participant completes their 90-day follow-up.

Industry Context

StockSavvy.ai notes that DiaMedica's focus on preeclampsia, fetal growth restriction, and acute ischemic stroke addresses significant unmet medical needs in cardiovascular and pregnancy-related diseases. The company's lead candidate, DM199, is a recombinant form of KLK1 protein, a therapeutic modality with established use in Asia for stroke, suggesting a potential for broader therapeutic application if clinical trials prove successful.

Comparison to Industry Standards

• The company is advancing multiple clinical programs simultaneously, which is common for biopharmaceutical companies seeking to diversify their pipeline and address various indications.
• The use of investigator-sponsored trials (ISTs) for early-stage research, such as the FGR study, is a standard practice to leverage external expertise and funding.
• The progression to Phase 2/3 trials for acute ischemic stroke (ReMEDy2) and Phase 2 for early-onset preeclampsia aligns with typical drug development pathways.
• The company's cash runway projection into Q4 2027 is a critical metric for investors, indicating the time available to achieve further clinical milestones before requiring additional funding.

Stakeholder Impact

• Shareholders: The progress in clinical trials and extended cash runway are positive indicators, but increased R&D spending and net losses may require future capital raises.
• Patients: Advancements in trials for preeclampsia, FGR, and AIS offer potential for new therapeutic options for serious conditions.
• Healthcare Providers: The KOL event and upcoming trial data will provide insights into the potential of DM199 for treating these conditions.

Next Steps

• Present preliminary, interim topline results from the first two FGR cohorts at the November 24 KOL event.
• Initiate the open-label, Phase 2 dose-finding study in early-onset preeclampsia in Canada and the UK.
• Submit data package to FDA for review regarding the rat reproductive toxicity study for the preeclampsia program.
• Conduct the interim analysis of the ReMEDy2 Phase 2/3 AIS trial in Q1 2027.
• Continue enrollment in the ReMEDy2 trial, with the final sample size ranging between 300 and 728 participants.
• Initiate Part 1b and Part 2 of the Phase 2 PE study by the end of 2026.

Key Dates

Recommendation

The company is making steady progress in its clinical development programs, particularly with the FGR and AIS trials reaching key enrollment milestones. The extended cash runway is also a positive. However, the increased R&D spend, continued net losses, and the need for further data to satisfy FDA requirements for the preeclampsia IND application warrant a cautious approach. Investors should await interim analysis results and further regulatory feedback before considering a stronger position.

Keywords

preeclampsia, fetal growth restriction, acute ischemic stroke, DM199, clinical trials, biopharmaceutical, drug development, Phase 2 trial